OMCL logo

Omnicell, Inc. Stock Price

NasdaqGS:OMCL Community·US$1.5b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

OMCL Share Price Performance

US$33.08
0.49 (1.50%)
US$61.29
Fair Value
US$33.08
0.49 (1.50%)
46.0% undervalued intrinsic discount
US$61.29
Fair Value
Price US$33.08
AnalystConsensusTarget US$61.29
AnalystLowTarget US$45.00
AnalystHighTarget US$70.00

OMCL Community Narratives

·
Fair Value US$61.29 46.0% undervalued intrinsic discount

OmniSphere Adoption Will Simplify Healthcare Medication Management

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
·
Fair Value US$45 26.5% undervalued intrinsic discount

Government Cost Containment And Cybersecurity Burdens Will Impair Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$70 52.7% undervalued intrinsic discount

Aging Population And Digital Transformation Will Drive Medication Automation

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Trending Discussion

No trending discussion available.

Updated Narratives

OMCL logo

OMCL: Aging Systems And Pipeline Conversion Will Drive Higher Future Earnings Multiple

Fair Value: US$45 26.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
OMCL logo

OMCL: Cabinet Replacement Cycle Will Support Higher Multiple As New Leadership Executes

Fair Value: US$70 52.7% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
OMCL logo

OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Demand

Fair Value: US$61.29 46.0% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with proven track record.

0 Risks
4 Rewards

Omnicell, Inc. Key Details

US$1.2b

Revenue

US$698.0m

Cost of Revenue

US$548.7m

Gross Profit

US$509.6m

Other Expenses

US$39.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.86
44.01%
3.13%
13.0%
View Full Analysis

About OMCL

Founded
1992
Employees
3485
CEO
Randall Lipps
WebsiteView website
www.omnicell.com

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Recent OMCL News & Updates

Seeking Alpha Aug 25

Omnicell: Offers Good Value, But Uncertainty Remains

Summary Omnicell, which is down by -24% on a YTD basis, has also underperformed other medtech and small-cap healthcare stocks by a large margin. OMCL faces near-term headwinds, with YoY revenue contraction for the first time in seven quarters and increased uncertainty around product bookings for FY26. OMCL's sales cycle for its new-gen Titan XT system remains slow amid heightened competition and a lack of alacrity to upgrade from  old-gen systems. Gross margins in H2 are going to be pressured by memory chip shortages, leading to higher sourcing costs and a projected 50 bps margin hit in FY26. However, the weakness in the stock price has also made the stock emerge as one of the strong value bets within the small-cap healthcare universe. Read the full article on Seeking Alpha
Narrative Update Aug 14

OMCL: Aging Systems And Pipeline Conversion Will Drive Higher Future Earnings Multiple

Analysts have trimmed their Omnicell price targets to a range centered around $45, citing a shift to a $45 fair value estimate from $50, even as they highlight strong recent results and note that the company’s pipeline and aging installed base could support bookings over time. Analyst Commentary on Omnicell Recent research commentary on Omnicell points to a mixed picture.

Recent updates

No updates